{
  "pathway_name": "primary-and-secondary-myelofibrosis-clinical-pathways-v2-2024-508h",
  "original_file": "primary-and-secondary-myelofibrosis-clinical-pathways-v2-2024-508h_extracted.json",
  "processed_at": "2025-03-29T01:32:33.192621",
  "complete_summary": {
    "response": "# Primary and Secondary Myelofibrosis Clinical Pathway\n\n## I. Diagnostic Approach\n\n### Initial Diagnostic Workup\n1. **Required Laboratory and Imaging Studies**\n   - Peripheral blood smear with evaluation for leukoerythroblastic picture and differential\n   - Bone marrow biopsy with reticulin stain (required)\n   - Consider trichrome stain if reticulin fibrosis is moderate/marked\n   - Bone marrow aspirate, core and clot section (anticipate possible \"dry tap\")\n\n2. **Molecular and Cytogenetic Testing**\n   - **Flow Cytometry**: Leukemia/lymphoma panel (bone marrow aspirate or peripheral blood)\n   - **FISH Testing**: t(9;22) BCR::ABL1\n   - **Karyotyping**: Bone marrow karyotype\n   - **Comprehensive NGS Panel**: Including ASXL1, BCOR, BCORL1, CBL, CUX1, DNMT3A, ETV6, EZH2, FLT3, IDH1, IDH2, KRAS, NPM1, NRAS, PHF6, RAD21, RUNX1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, ZRSR2, JAK2, CALR, MPL, SETBP1, ETNK1, PTPN11, and NF1\n\n### Diagnostic Considerations\n- Document spleen size at baseline\n- Multiple risk assessment tools available: DIPSS+, GIPSS, MIPSS70+ v2.0, MYSEC\n- Consider secondary myelofibrosis when making diagnosis\n- Rule out non-myeloid diseases that may present with fibrosis (e.g., hairy cell leukemia, metastatic cancer)\n\n## II. Initial Treatment Decision Pathway\n\n### First Decision Point: Transplant Candidacy\n1. **If Transplant Candidate**:\n   - Refer eligible patients for transplant evaluation\n   - Consider early transplant discussion for patients <70 years or >70 with low comorbidity\n\n2. **If Not Transplant Candidate**:\n   - Proceed to symptom assessment\n\n### Symptom Assessment and Initial Therapy\n1. **If Asymptomatic**:\n   - Observation recommended\n\n2. **If Symptomatic**:\n   - **For Anemia without Symptomatic Splenomegaly** (Hgb < 10 g/dL):\n     * First-line: **Danazol**\n     * If non-responsive: Switch to **Momelotinib**\n   \n   - **For Anemia with Symptomatic Splenomegaly**:\n     * Treatment: **Momelotinib**\n   \n   - **For Severe Thrombocytopenia** (platelets < 50):\n     * Treatment: **Pacritinib**\n   \n   - **For Thrombocytopenia** (platelets \u2265 50):\n     * Treatment: **Ruxolitinib**\n   \n   - **For Leukocytosis > 20 \u00d7 10\u2079/L and Thrombocytosis > 500**:\n     * Appropriate therapy based on other clinical parameters\n\n## III. Progressive, Relapsed/Refractory or Accelerated Disease\n\n### Assessment for Disease Progression\n1. **Indicators of Progressive Disease**:\n   - Rapidly enlarging spleen\n   - Worsening leukocytosis + blasts\n   - Onset of transfusion dependency\n   - Unexplained cytopenia\n   - Worsening B symptoms\n   - Clonal evolution\n\n2. **Decision Point: AML Progression?**\n   - **If YES**:\n     * Option 1: Refer to transplant\n     * Option 2: Follow AML first-line pathway\n   \n   - **If NO**: Assess for worsening symptoms\n\n### Treatment for Progressive Disease (Without AML Progression)\n\n1. **Progressive Anemia** with/without symptomatic splenomegaly:\n   - **Prior momelotinib?**\n     * Yes: Administer **Pacritinib**\n     * No: Administer **Momelotinib**\n\n2. **Progressive Splenomegaly \u00b1 Symptoms with Platelets < 50K**:\n   - **Prior pacritinib?**\n     * Yes: Administer **Momelotinib**\n     * No: Administer **Pacritinib**\n\n3. **Progressive Splenomegaly \u00b1 Symptoms with Platelets \u2265 50K**:\n   - **Prior ruxolitinib?**\n     * Yes: Administer **Fedratinib**\n     * No: Administer **Ruxolitinib**\n\n## IV. Treatment Considerations and Supportive Care\n\n### JAK Inhibitor Management\n1. **General Considerations**:\n   - Responses may be delayed\n   - Cytopenias can worsen during initial therapy\n   - Titrate JAK2 inhibitors to maximal tolerated dose\n   - Allow 3-6 months of uninterrupted therapy before determining efficacy\n   - Implement gradual taper when discontinuing ruxolitinib\n\n2. **Fedratinib-Specific Considerations**:\n   - Risk of serious/fatal encephalopathy including Wernicke encephalopathy\n   - Assess thiamine levels before starting, periodically during treatment, and as clinically indicated\n   - Do not start in patients with thiamine deficiency\n   - Replete thiamine prior to treatment initiation\n   - Immediately discontinue and initiate parenteral thiamine if encephalopathy suspected\n   - Note moderate to high emetogenic potential\n\n### Supportive Care\n1. **Transfusion Management**:\n   - Monitor for iron overload in transfusion-dependent patients\n   - Consider chelation therapy when indicated\n\n2. **Thrombosis Prevention**:\n   - Anti-platelet therapy can be continued in patients with moderate to severe thrombocytopenia to mitigate thrombosis risk\n\n3. **Clinical Trials**:\n   - Consider clinical trials throughout treatment pathway\n   - For assistance: CancerClinicalTrialsNavigation@va.gov\n\n## V. VA-Specific Considerations\n- Primary and Secondary Myelofibrosis are currently **not** presumptive conditions for VA disability benefits\n- Veterans must establish direct service connection to qualify for related disability benefits\n- NGS testing may be covered under VA sponsored grant through GLA Foundation Medicine\n\n## Important Definitions\n- **Constitutional Symptoms**: Fatigue, fever, night sweats, weight loss, anemia, thrombocytopenia, and splenomegaly attributable to myelofibrosis\n- **Bone Marrow Assessment**: Consider bone marrow biopsy if concerns for progression to acute leukemia or if results would change management\n- **Before Changing Therapy**: Optimize dosing of current medication\n\nThis pathway represents a comprehensive approach to the diagnosis and management of primary and secondary myelofibrosis. Clinical judgment remains essential in applying these guidelines to individual patients.",
    "thinking": "# Comprehensive Summary of Primary and Secondary Myelofibrosis Clinical Pathway\n\nI'll create a comprehensive clinical pathway summary based on the provided information, organizing it into a logical, clinically-relevant structure that would serve as a reference document for healthcare providers. I'll include all key decision points, diagnostic criteria, treatment options, and clinical workflows.\n\n## Introduction and Overview\n\nPrimary and secondary myelofibrosis are myeloproliferative neoplasms characterized by bone marrow fibrosis, extramedullary hematopoiesis, and variable clinical presentations. This clinical pathway provides evidence-based guidance on the diagnosis, risk assessment, and management of these conditions for healthcare providers.\n\n## I. Diagnostic Pathway\n\n### A. Initial Diagnostic Workup\n\n1. **Clinical Suspicion for Myelofibrosis**\n   - Cytopenias\n   - Splenomegaly \n   - Constitutional symptoms\n   - Leukoerythroblastic blood picture\n\n2. **Required Diagnostic Tests**\n   - **Peripheral Blood Assessment**\n     - Complete blood count with differential\n     - Peripheral blood smear examination\n     - Evaluation for leukoerythroblastic picture\n     - Assessment of peripheral blood blasts\n\n   - **Bone Marrow Assessment**\n     - Bone marrow biopsy with reticulin stain (required)\n     - Consider trichrome stain if reticulin fibrosis is moderate or marked\n     - Bone marrow aspirate (anticipate possible \"dry tap\")\n     - Core biopsy and clot section\n\n   - **Cytogenetic and Molecular Testing**\n     - Flow cytometry (leukemia/lymphoma panel)\n       * Specimen: Bone marrow aspirate or peripheral blood\n     - FISH testing for t(9;22) BCR::ABL1\n       * Specimen: Bone marrow aspirate or peripheral blood\n     - Bone marrow karyotype\n       * Specimen: Bone marrow aspirate or peripheral blood\n     - Comprehensive molecular testing (when bone marrow morphology is consistent with myeloid neoplasm with myelofibrosis)\n       * NGS panel including: ASXL1, BCOR, BCORL1, CBL, CUX1, DNMT3A, ETV6, EZH2, FLT3, IDH1, IDH2, KRAS, NPM1, NRAS, PHF6, RAD21, RUNX1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, ZRSR2, JAK2, CALR, MPL, SETBP1, ETNK1, PTPN11, and NF1\n       * Optional gene: DDX41\n       * Specimen: Bone marrow aspirate or peripheral blood\n\n### B. Diagnostic Considerations\n\n1. **Differential Diagnosis**\n   - Rule out non-myeloid diseases that may present with fibrosis:\n     * Hairy cell leukemia\n     * Metastatic breast cancer\n     * Classic Hodgkin lymphoma\n   - Note: Non-myeloid diseases presenting with fibrosis should not be worked up as myeloid neoplasm\n\n2. **Risk Assessment Tools**\n   - DIPSS+\n   - GIPSS\n   - MIPSS70+ v2.0\n   - MYSEC (for secondary myelofibrosis)\n\n3. **Baseline Documentation**\n   - Document spleen size at baseline\n   - Consider secondary myelofibrosis in diagnosis\n\n## II. Primary Treatment Pathway\n\n### A. Initial Treatment Strategy Decision\n\n1. **Transplant Candidacy Assessment**\n   - **For transplant candidates**:\n     * Refer eligible patients for stem cell transplantation evaluation\n     * Consider early transplant discussion for patients:\n       - Age <70 years\n       - Age >70 with low comorbidity\n\n   - **For non-transplant candidates**:\n     * Proceed to symptom assessment\n\n2. **Symptom Assessment**\n   - **For asymptomatic patients**:\n     * Observation recommended\n\n   - **For symptomatic patients**:\n     * Proceed to symptom-directed therapy\n\n### B. Symptom-Directed Therapy\n\n1. **Anemia Management** (Hgb < 10 g/dL)\n   - **Anemia without symptomatic splenomegaly**:\n     * First-line: Danazol\n     * If non-responsive: Switch to Momelotinib\n\n   - **Anemia with symptomatic splenomegaly**:\n     * Treatment: Momelotinib\n\n2. **Platelet Abnormality Management**\n   - **Severe thrombocytopenia** (platelets < 50):\n     * Treatment: Pacritinib\n\n   - **Thrombocytopenia** (platelets \u2265 50):\n     * Treatment: Ruxolitinib\n\n   - **Leukocytosis > 20 \u00d7 10\u2079/L and thrombocytosis > 500**:\n     * Appropriate JAK inhibitor therapy based on other clinical parameters\n\n## III. Management of Progressive/Refractory Disease\n\n### A. Assessment for Disease Progression\n\n1. **Progressive Disease Indicators**:\n   - Rapidly enlarging spleen\n   - Worsening leukocytosis + blasts\n   - Onset of transfusion dependency\n   - Unexplained cytopenia\n   - Worsening B symptoms\n   - Clonal evolution\n\n2. **AML Progression Assessment**\n   - Consider bone marrow biopsy if concerns for progression to acute leukemia\n   - **If progressed to AML**:\n     * Option 1: Refer to transplant\n     * Option 2: Follow AML first-line pathway\n\n   - **If not progressed to AML**:\n     * Assess for worsening symptoms\n\n### B. Treatment for Progressive Disease (Not Progressed to AML)\n\n1. **Progressive Anemia** (with or without symptomatic splenomegaly)\n   - **Prior momelotinib treatment?**\n     * Yes: Administer Pacritinib\n     * No: Administer Momelotinib\n\n2. **Progressive Splenomegaly \u00b1 Symptoms with Platelets < 50K**\n   - **Prior pacritinib treatment?**\n     * Yes: Administer Momelotinib\n     * No: Administer Pacritinib\n\n3. **Progressive Splenomegaly \u00b1 Symptoms with Platelets \u2265 50K**\n   - **Prior ruxolitinib treatment?**\n     * Yes: Administer Fedratinib\n     * No: Administer Ruxolitinib\n\n## IV. Treatment Considerations and Supportive Care\n\n### A. JAK Inhibitor Management\n\n1. **General Considerations**\n   - Responses may be delayed\n   - Cytopenias can worsen during initial therapy\n   - Titrate JAK2 inhibitors to maximal tolerated dose\n   - Allow 3-6 months of uninterrupted therapy before determining efficacy\n   - Minimize therapy interruptions\n\n2. **Discontinuation Protocol**\n   - Implement gradual taper when discontinuing ruxolitinib for non-thrombocytopenia reasons\n\n3. **Fedratinib-Specific Considerations**\n   - Risk of serious/fatal encephalopathy including Wernicke encephalopathy\n   - Assess thiamine levels in all patients:\n     * Before starting treatment\n     * Periodically during treatment\n     * As clinically indicated\n   - Do not start in patients with thiamine deficiency\n   - Replete thiamine prior to treatment initiation\n   - Immediately discontinue and initiate parenteral thiamine if encephalopathy is suspected\n   - Note moderate to high emetogenic potential\n   - Continue monitoring and checking thiamine levels\n\n### B. Supportive Care\n\n1. **Transfusion Management**\n   - Monitor for iron overload in transfusion-dependent patients\n   - Monitor iron studies\n   - Consider chelation therapy when indicated\n\n2. **Thrombosis Prevention**\n   - Anti-platelet therapy can be continued to mitigate thrombosis risk in patients with moderate to severe thrombocytopenia\n\n3. **Clinical Trials**\n   - Clinical trials should always be considered throughout the treatment pathway\n   - For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov\n\n## V. VA-Specific Considerations\n\n1. **Disability Benefits Status**\n   - Primary and Secondary Myelofibrosis are currently **not** presumptive conditions for VA disability benefits\n   - Veterans must establish a direct service connection to qualify for related disability benefits\n   - For more information, visit va.gov (U.S. Department of Veterans Affairs website)\n\n2. **Testing Coverage**\n   - Initial diagnostic testing (stain, flow cytometry, FISH, karyotyping) has no National Prosthetics and Orthotics Programs (NPOP) coverage indicated\n   - NGS testing may be covered under VA sponsored grant through GLA Foundation Medicine (no cost to facility)\n   - Reach out to GLA for information on NGS testing under VA sponsored grant\n\n## Appendix: Definitions and Key Terms\n\n1. **Constitutional Symptoms**: Include fatigue, fever, night sweats, weight loss, anemia, thrombocytopenia, and splenomegaly attributable to myelofibrosis.\n\n2. **Progressive Disease**: Characterized by rapidly enlarging spleen, worsening leukocytosis + blasts, onset of transfusion dependency, unexplained cytopenia, worsening B symptoms, or clonal evolution.\n\nThis comprehensive pathway provides evidence-based guidance for the management of primary and secondary myelofibrosis. Clinical judgment should be exercised in individual patient scenarios, and consideration of clinical trials is encouraged at all stages of disease management."
  }
}